Effectiveness of Asiaticoside as Intracanal Medication on Infectious/Inflammatory Contents in Teeth With Apical Periodontitis

Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age20-60
SponsorMansoura University

About this trial

The objective of this study is to investigate \"clinically\" the effectiveness of Asiaticoside based intracanal medication compared to the commonly used intracanal medicaments (calcium hydroxide Ca(OH)2 and Ledermix) on the levels of bacteria and inflammatory cytokines in root canals and periradicular tissues of teeth with apical periodontitis.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

Reporting systemic disease.

Teeth that could not be isolated with rubber dam.

Teeth with periodontal pockets deeper than 3 mm.

Trial design

Design model

Crossover

Treatments tested in this trial

  • Calcium Hydroxide Intracanal medication

    Drug

    Calcium Hydroxide Intracanal medication

  • Leddermix Intracanal medication

    Drug

    Leddermix Intracanal medication

  • Asiaticoside Intracanal medication

    Drug

    Asiaticoside Intracanal medication

Treatment groups

36 Participants
are divided into 3 treatment groups
Group A: Calcium HydroxideActive comparator 1 intervention
Group B: LeddermixActive comparator 1 intervention
Group C: AsiaticosideActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

counting the number of colonies forming units of bacterial cells Microbiology cell culturing (manual counting technique to the bacterial cells) [Time Frame: up to 7 months]

counting the number of colonies forming units of bacterial cells Microbiology cell culturing (manual counting technique to the bacterial cells) \[Time Frame: up to 7 months\]

Time frame
up to 7 months

Secondary outcomes

1

using enzyme-linked immunosorbent assay (ELISA test) to measure the amount of Inflammatory Cytokines (TNF-α), (IL-1β) and (PG2) ELISA test to measure the amount of tumor necrotizing factor (TNF-α), interleukin 1β(IL-1β) and prostaglandin E2 (PG2)

using enzyme-linked immunosorbent assay (ELISA test) to measure the amount of Inflammatory Cytokines (TNF-α), (IL-1β) and (PG2) ELISA test to measure the amount of tumor necrotizing factor (TNF-α), interleukin 1β(IL-1β) and prostaglandin E2 (PG2)

Time frame
up to 25 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.